olaratumab + ramucirumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adult Glioblastoma Multiforme
Conditions
Adult Glioblastoma Multiforme
Trial Timeline
Jul 1, 2010 → Mar 4, 2014
NCT ID
NCT00895180About olaratumab + ramucirumab
olaratumab + ramucirumab is a phase 2 stage product being developed by Eli Lilly for Adult Glioblastoma Multiforme. The current trial status is completed. This product is registered under clinical trial identifier NCT00895180. Target conditions include Adult Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00895180 | Phase 2 | Completed |
Competing Products
20 competing products in Adult Glioblastoma Multiforme
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 + sotorasib | BridgeBio Pharma | Phase 1 | 30 |
| Daridorexant + Placebo | Idorsia | Phase 1 | 28 |
| SON-1010 (IL12-FHAB) | Sonnet BioTherapeutics | Phase 1 | 28 |
| Somatropin | Eli Lilly | Phase 3 | 77 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Pegilodecakin | Eli Lilly | Phase 1 | 33 |
| eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Lazertinib(G001) + Lazertinib(G002) | Yuhan | Phase 1 | 33 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |
| Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride | Eisai | Phase 1 | 33 |